Therefore, although NLRC4 is associated with infectious diseases and MAS, high levels of IL-18 seem to be only associated with the latter, and patients with refractory severe MAS have better therapeutic effects after using IL-18 blockers and gamma interferon blockers (a cytokine induced by IL-18) (105). Here, NLRC4 is linked to macrophage activation syndrome.